Abstract
Background: Ataxia telangiectasia mutated and Rad3-related kinase (ATR) mediates cellular response to replication stress and DNA damage. Camonsertib is a potent and selective ATR inhibitor with strong pre-clinical efficacy, promising clinical activity (NCT04497116) but results in rapid monocytopenia leading to dose limiting anemia potentially implicating a disturbance in iron homeostasis. Pre-clinically, dosing 3 days on/4 off mitigates anemia without compromising efficacy, allowing reticulocyte regeneration between doses.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
